A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublitu
The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting
| Condition(s) | Relapsing Multiple Sclerosis, Multiple Sclerosis |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting |
| Who can participate | Inclusion Criteria: 1. Confirmed Multiple Sclerosis (MS) diagnosis. 2. Participants who have not received any BRIUMVI® (ublituximab-xiiy) infusion prior to study start. Participants who have been prescribed BRIUMVI® (ublituximab-xiiy) but have not yet received their first infusion on Day 1 of 150 milligrams (mg) can be included. Exclusion Criteria: 1. Have received any live or live-attenuated vaccines (including for varicella-zoster virus or measles) within 4 weeks prior to first BRIUMVI® (ublituximab-xiiy) administration or any non-live vaccines within 2 weeks prior to first BRIUMVI® (ublituximab-xiiy) administration. 2. Any active infection (e.g., active Hepatitis B virus \[HBV\]) 3. Concurrent participation in any interventional MS trials, or planned concurrent treatment with other Mult |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | TG Therapeutics, Inc. |
| Locations | Birmingham, Alabama, United States; Huntsville, Alabama, United States; Mobile, Alabama, United States; Gilbert, Arizona, United States; Phoenix, Arizona, United States; Scottsdale, Arizona, United States (+82 more sites) |
| Start date | 2024-07-22 |
| NCT ID | NCT06433752 |
| Official listing | https://clinicaltrials.gov/study/NCT06433752 |